Phaseline

Companies › TLC Biopharmaceuticals

TLC Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 40 registered trials: 23 Phase 4, 11 Phase 3, 6 Phase 2; Neurology, Cardiovascular, Gastroenterology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ropivacaine (TLC590)
Sodium channel alpha subunit blocker
Ion channelsPhase 3Postoperative Pain; Postsurgical Pain Management; End Stage Renal Disease (ESRD); Hepatic Resection …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07259772Ropivacaine (TLC590)Phase 4End Stage Renal Disease (ESRD)GenitourinaryMar 2021
NCT04849455Ropivacaine (TLC590)Phase 4Hepatic ResectionGastroenterologyMay 2023
NCT05515809Ropivacaine (TLC590)Phase 3Cardiac SurgeryCardiovascularJun 2025
NCT06519929Ropivacaine (TLC590)Phase 4Rib FracturesOtherAug 2025
NCT06784882Ropivacaine (TLC590)Phase 4Acute Postoperative PainOtherDec 2025
NCT07290595Ropivacaine (TLC590)Phase 2Post Operative AnalgesiaCardiovascularFeb 2026
NCT07290595Ropivacaine (TLC590)Phase 2Post Operative AnalgesiaCardiovascularFeb 2026
NCT07222748Ropivacaine (TLC590)Phase 3Postoperative PainOtherJun 2026
NCT06574269Ropivacaine (TLC590)Phase 2Postsurgical Pain ManagementOtherJul 2026
NCT05953766Ropivacaine (TLC590)Phase 2Post-operative PainOtherJul 2026
NCT06511765Ropivacaine (TLC590)Phase 3LumbagoOtherSep 2026
NCT03737604Ropivacaine (TLC590)Phase 4Transplant;Failure,KidneyGenitourinarySep 2026
NCT03230565Ropivacaine (TLC590)Phase 4Surgical Procedure, UnspecifiedOtherDec 2026
NCT04130464Ropivacaine (TLC590)Phase 4HysterectomyOtherDec 2026
NCT04130464Ropivacaine (TLC590)Phase 4HysterectomyOtherDec 2026
NCT06189781Ropivacaine (TLC590)Phase 4Cerebral PalsyNeurologyDec 2026
NCT06189781Ropivacaine (TLC590)Phase 4Cerebral PalsyNeurologyDec 2026
NCT07349810Ropivacaine (TLC590)Phase 4Post Operative PainOtherDec 2026
NCT07006168Ropivacaine (TLC590)Phase 4Patella FractureOtherDec 2026
NCT03796572Ropivacaine (TLC590)Phase 4Fractures, ClosedOtherJan 2027
NCT06875427Ropivacaine (TLC590)Phase 3Anterior Cruciate LigamentOtherJan 2027
NCT06008795Ropivacaine (TLC590)Phase 2Subarachnoid Hemorrhage, AneurysmalCardiovascularJan 2027
NCT07023094Ropivacaine (TLC590)Phase 4Hip DiseaseOtherJan 2027
NCT07023094Ropivacaine (TLC590)Phase 4Hip DiseaseOtherJan 2027
NCT07023094Ropivacaine (TLC590)Phase 4Hip DiseaseOtherJan 2027
NCT07023094Ropivacaine (TLC590)Phase 4Hip DiseaseOtherJan 2027
NCT06406010Ropivacaine (TLC590)Phase 4Anesthesia, LocalOtherFeb 2027
NCT05642026Ropivacaine (TLC590)Phase 4Rib FracturesOtherFeb 2027
NCT05889741Ropivacaine (TLC590)Phase 2Stress Disorders, Post-TraumaticPsychiatryMar 2027
NCT03632044Ropivacaine (TLC590)Phase 4Mouth AbnormalitiesOtherMay 2027
NCT04011150Ropivacaine (TLC590)Phase 3Labor PainOtherAug 2027
NCT07116343Ropivacaine (TLC590)Phase 4Cardiac SurgeryCardiovascularSep 2027
NCT07180979Ropivacaine (TLC590)Phase 4Hip OsteoarthritisImmunologySep 2027
NCT07180979Ropivacaine (TLC590)Phase 4Hip OsteoarthritisImmunologySep 2027
NCT07092566Ropivacaine (TLC590)Phase 3Renal CarcinomaOncologyOct 2027
NCT07666178Ropivacaine (TLC590)Phase 3Erector Spinae Plane BlockOtherDec 2027
NCT02278601Ropivacaine (TLC590)Phase 3Breakthrough PainOtherDec 2027
NCT07414706Ropivacaine (TLC590)Phase 3Intravenous LidocaineOtherJun 2028
NCT04065009Ropivacaine (TLC590)Phase 3Advanced Ovarian CancerOncologySep 2028
NCT05969457Ropivacaine (TLC590)Phase 3Hysterotomy; Affecting FetusOtherSep 2029

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine Industrial Farmacéutica Cantabria

Companies built like this

Shenzhen Ausa Pharmed LXO Ireland Xenon Pharmaceuticals Newron Pharmaceuticals Lupin

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.